Mastocytosis is a rare condition where an excessive amount of mast cells gather in the organs and tissues of the body. It can affect the skin, lymph nodes, bone marrow, and other organ systems.

Systemic mastocytosis is a disease where too many abnormal mast cells (a type of white blood cell) build up in your skin and other organs. You might get a variety of symptoms, including itchy skin ...

If you have systemic mastocytosis, your health care provider may recommend a medicine to treat it. One such medicine is Ayvakit (avapritinib), an oral tablet. Systemic mastocytosis is a rare ...

Systemic mastocytosis (SM) is a rare blood disorder in which the body produces too many mast cells. Part of the immune response, mast cells are a type of white blood cell that releases histamine ...

DelveInsight’s, “Systemic Mastocytosis Pipeline Insight, 2025,” report provides comprehensive insights about 8+ companies and ...

Systemic mastocytosis is a rare health condition in which too many mast cells (a type of immune system cell) build up in the body, causing allergic reactions and other health issues. This disorder ...

In September of 2000, the world's leading experts in MC met to discuss and present data at the "Year 2000 Working Conference on Mastocytosis," held in Vienna, Austria. Table 1 presents a uniform ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline with FDA-approved Ayvakit ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.